Urgent

Autoimmune haemolytic anaemia - management

AIHA mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Antibody-mediated red cell destruction, warm (IgG) or cold (IgM) type, confirmed by a positive direct antiglobulin test. Management targets the immune process, supports oxygenation, and seeks underlying lymphoproliferative or autoimmune disease.

Red flags

  • Haemoglobin falling rapidly with cardiac compromise
  • Haemoglobinuria with renal impairment
  • Signs of lymphoma (nodes, B symptoms)
  • Concurrent thrombocytopenia (Evans syndrome)
  • Cold AIHA with acrocyanosis and massive agglutination

Assessment

Differential diagnosis

  • Hereditary haemolytic anaemia (spherocytosis, G6PD)
  • Microangiopathic haemolysis (TTP/HUS)
  • Drug-induced haemolysis
  • PNH
  • Cold agglutinin disease
  • Lymphoproliferative disorder

Investigations

  • FBC, film (spherocytes, agglutination), reticulocytes
  • Direct antiglobulin test (IgG and C3d pattern)
  • LDH, haptoglobin, unconjugated bilirubin
  • Thermal amplitude / cold agglutinin titre if cold type suspected
  • Blood group and antibody screen (transfusion planning)
  • Screen for secondary cause: CT, serum electrophoresis, autoimmune serology, viral screen

Management

  • Confirm haemolysis (high LDH, high reticulocytes, low haptoglobin, high bilirubin) and positive DAT
  • Classify warm vs cold by DAT pattern and thermal characteristics
  • Assess severity and haemodynamic/cardiac impact
  • For warm AIHA, start corticosteroids first line
  • Add folic acid and thromboprophylaxis (active haemolysis is prothrombotic)
  • Transfuse if critically symptomatic despite cross-match difficulty - give least-incompatible units, never withhold in emergency
  • For refractory/relapsing warm AIHA use rituximab; consider splenectomy or further immunosuppression
  • For cold agglutinin disease, keep the patient warm, avoid steroids/splenectomy, use rituximab-based therapy and consider sutimlimab
  • Investigate and treat any secondary cause (lymphoma, CLL, SLE, infection)
  • Taper steroids slowly once haemoglobin stabilises and monitor for relapse

Drugs & doses

Prednisolone 1 mg/kg PO daily (warm AIHA, then taper)
Methylprednisolone 1 g IV daily for 1-3 days in severe cases
Rituximab 375 mg/m2 IV weekly for 4 weeks (second line / cold agglutinin)
Folic acid 5 mg PO daily
Sutimlimab per protocol for cold agglutinin disease

Disposition

Admit if severe or rapidly falling Hb; haematology-led management; outpatient follow-up for taper and relapse monitoring.

Complications & pitfalls

  • Venous thromboembolism during active haemolysis
  • Steroid toxicity
  • Relapse on tapering
  • Transfusion reaction from pan-reactive antibodies
  • Progression of underlying lymphoproliferative disease

Exam pearls

  • Never withhold life-saving transfusion because of cross-match incompatibility
  • Steroids are ineffective in cold agglutinin disease - keep warm and use rituximab
  • Active haemolysis warrants thromboprophylaxis
  • Always hunt for an underlying lymphoproliferative or autoimmune disorder
  • Evans syndrome = AIHA plus immune thrombocytopenia

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.